Your experience on this site will be improved by allowing cookies - see details ALLOW COOKIES HOME INVESTORS PRODUCTS ABOUT RESPONSIBILITY NEWS CAREERS SEARCH News > Press Releases > Actavis Is Now Allergan PRESS RELEASES MEDIA CONTACTS 03.17.2015 | News Actavis is now Allergan Actavis plc (NYSE: ACT) has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction valued at approximately $70.5 billion. The combination creates one of the world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. Actavis Products in the U.S. To report adverse events, product complaints, or for medical/product related questions related to Actavis or Watson manufactured U.S. products, call: +1-800-272-5525 Actavis Products outside the U.S. To report adverse events and product complaints for Watson, Actavis, Arrow and Warner Chilcott products outside the U.S. please contact the Marketing Authorization Holder for the product. Contact details for Marketing Authorization Holder are listed in the leaflet or labeling accompanying the product. U.S. GENERICS Allergan’s U.S. Generics business continues to operate as Actavis. Actavis U.S. CONTACT US If you have questions about the Company or request additional information, please contact Allergan COUNTRY WEBSITES COMPLIANCE DISCLAIMER TERMS PRIVACY SITEMAP © ALLERGAN 2015